Görlich Group

The Görlich Group is a family office based in Berlin, Germany, with a rich history in real estate investments. Over the years, they have placed 320 real estate funds, amassing a transaction volume of €4.6 billion. Their expertise spans various aspects of asset and property management within Germany. In 2024, the group expanded its investment horizon by establishing a BaFin-registered capital management company, aiming to launch its first biotechnology fund with a target volume of up to €30 million. This move underscores their commitment to diversifying their portfolio and embracing innovative sectors. The Görlich Group's approach is characterized by a blend of tradition and innovation, focusing on forward-looking asset management both domestically and internationally. They emphasize a collaborative investment strategy, working closely with clients to identify and seize entrepreneurial opportunities. Their core values include a readiness to preserve, rethink, and dare to try something new, reflecting a dynamic and adaptable investment philosophy. This philosophy is evident in their recent ventures, such as their involvement with 4TEEN4 Pharmaceuticals GmbH, a biotech startup developing treatments for cardiogenic shock. Through this investment, the Görlich Group aims to provide investors with access to cutting-edge medical technologies, highlighting their proactive approach to emerging industries. Their history and strategic initiatives position them as a significant player in both the real estate and biotechnology investment landscapes.